LOGIN  |  REGISTER
Recursion
Recursion

Acadia Healthcare to Participate in Stephens Annual Investment Conference

November 12, 2024 | Last Trade: US$23.91 4.78 -16.66

FRANKLIN, Tenn. / Nov 12, 2024 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the Stephens Annual Investment Conference, November 19 – 21, 2024, in Nashville, Tennessee.

In connection with the conference, there will be an online webcast of the Company’s presentation available on the Company’s website starting at 11:00 a.m. Eastern Time / 10:00 a.m. Central Time on Wednesday, November 20, 2024.

The live webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentation will also be available on the Company’s website for 30 days.

About Acadia

Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2024, Acadia operated a network of 260 behavioral healthcare facilities with approximately 11,300 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 80,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page